SEC Filing Summary: Form 13F-HR
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Gilead Sciences, Inc., an institutional investment manager, for the quarter ended June 30, 2026. The report was signed by Andrew D. Dickinson, Executive Vice President and Chief Financial Officer, on August 3, 2026. The filing includes holdings for Gilead Sciences, Inc. and one other included manager, Gilead Therapeutics A1 Unlimited Co.
Key Financial Metrics
As a Form 13F filing, this document reports equity holdings rather than the issuer's operational financial performance. Consequently, revenue, profit, cash flow, margins, debt, and liquidity metrics for Gilead Sciences, Inc. are not provided in this text.
- Total Value of Reported Holdings: $1,648,747,919
- Number of Holdings Reported: 5
- Number of Other Included Managers: 1
Material Changes
The filing text does not provide comparative data for the prior period; therefore, material changes in holdings value or composition cannot be determined from this document alone.
Guidance, Outlook, and Risks
This filing type does not contain management commentary, forward-looking guidance, risk factors, or contingencies regarding the company's business operations. It strictly discloses the equity securities held by the reporting manager.
Investor Verification Checklist
- Verify the total value of holdings ($1.65 billion) against the company's latest 10-Q or 10-K to understand the proportion of assets managed.
- Review the specific 5 holdings listed in the full schedule (not included in this summary text) to identify concentration risks.
- Confirm the identity of the "Other Included Manager" (Gilead Therapeutics A1 Unlimited Co) to understand the scope of the reporting entity.
- Note that this filing reflects investment positions, not the operating results of Gilead Sciences, Inc.